ArticlePloS one2013
Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Prognostic role of 14q32.31 miRNA cluster in various carcinomas: a systematic review and meta-analysis.Clinical & experimental metastasis · 2020Pooled it
- Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.PloS one · 2017Pooled it
- A potent small-chemical MBD2 inhibitor, KCC-07, induces selective cytotoxicity in hepatocellular and prostate cancer cells.Molecular biology reports · 2026Article
- The Mechanism of DNA Methylation and miRNA in Breast Cancer.International journal of molecular sciences · 2023Review
- Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro.International journal of molecular sciences · 2023Article
- Genetic or siRNA inhibition of MBD2 attenuates the UUO- and I/R-induced renal fibrosis via downregulation of EGR1.Molecular therapy. Nucleic acids · 2022Article
- Methyl-CpG-binding domain protein 2 contributes to renal fibrosis through promoting polarized M1 macrophages.Cell death & disease · 2022Article
- Increased Methyl-CpG-Binding Domain Protein 2 Promotes Cigarette Smoke-Induced Pulmonary Hypertension.Frontiers in oncology · 2022Article
- Induction ofScience signaling · 2021Article
- Serum long non‑coding RNA NNT‑AS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR‑496/RAP2C axis in colorectal cancer.Molecular medicine reports · 2021Article
- MBD2 mediates renal cell apoptosis via activation of Tox4 during rhabdomyolysis-induced acute kidney injury.Journal of cellular and molecular medicine · 2021Article
- miR-496 inhibits proliferation via LYN and AKT pathway in gastric cancer.Open medicine (Warsaw, Poland) · 2021Article
- Expression and clinical significance of methyl-CpG binding domain protein 2 in high-grade serous ovarian cancer.Oncology letters · 2020Article
- MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma.OncoTargets and therapy · 2020Article
- Epigenetic biomarker screening by FLIM-FRET for combination therapy in ER+ breast cancer.Clinical epigenetics · 2019Article
- MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI.Cell death & disease · 2017Article
- Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.Gynecologic oncology · 2016Article
- The dynamic nature of DNA methylation: a role in response to social and seasonal variation.Integrative and comparative biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Methylated DNA binding protein 2 (MBD2) binds methylated promoters and suppresses transcription in cis through recruitment of a chromatin modification repressor complex. We show here a new mechanism of action for MBD2: suppression of gene expression indirectly through activation of microRNA hsa-mir-496. Overexpression of MBD2 in breast epithelial cell line MCF-10A results in induced expression and demethylation of hsa-mir-496 while depletion of MBD2 in a human breast cancer cell lines MCF-7 and MDA-MB231 results in suppression of hsa-mir-496. Activation of hsa-mir-496 by MBD2 is associated with silencing of several of its target genes while depletion of MBD2 leads to induction of hsa-mir-496 target genes. Depletion of hsa-mir-496 by locked nucleic acid (LNA) antisense oligonucleotide leads to activation of these target genes in MBD2 overexpressing cells supporting that hsa-mir-496 is mediating in part the effects of MBD2 on gene expression. We demonstrate that MBD2 binds the promoter of hsa-mir-496 in MCF-10A, MCF-7 and MDA-MB-231 cells and that it activates an in vitro methylated hsa-mir-496 promoter driving a CG-less luciferase reporter in a transient transfection assay. The activation of hsa-mir-496 is associated with reduced methylation of the promoter. Taken together these results describe a novel cascade for gene regulation by DNA methylation whereby activation of a methylated microRNA by MBD2 that is associated with loss of methylation triggers repression of downstream targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.